Sutro Biopharma STRO Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$153.6M+37.4% | -$191.09M+16.0% | -$216.77M— | -$208.7M— | -$245.22M— | ||
| $6.7M-8.9% | $7.32M+1.5% | $7.57M+6.9% | $7.47M+6.4% | $7.36M+5.7% | ||
| $10.03M-58.5% | $14.01M-43.3% | $18.27M-26.9% | $23.26M-4.9% | $24.16M-3.2% | ||
| —— | $1.69M— | $1.27M— | $847K— | $423.5K— | ||
| -$1.13M+94.2% | -$4.69M+84.0% | -$4.69M+52.9% | -$912K+70.1% | -$19.7M-192% | ||
| —— | —— | —— | -$1.73M-179% | $722K-73.4% | ||
| -$6.2M— | $1.74M— | $71K— | —— | —— | ||
| -$18.34M-294% | -$19.35M-263% | -$7.45M— | $3.05M— | $9.46M— | ||
| -$512K+31.3% | -$571K+25.5% | -$616K+24.7% | -$639K+32.5% | -$745K+9.6% | ||
| -$66.91M— | -$69.73M— | —— | —— | —— | ||
| -$7.77M-16.3% | -$7.48M-16.5% | -$7.2M-16.7% | -$6.93M-16.8% | -$6.67M-27.1% | ||
| -$151.61M+25.7% | -$177.23M+11.8% | -$222.53M— | -$248.86M— | -$204.14M— | ||
| —— | —— | —— | —— | —— | ||
| $16.01M-88.4% | $45.01M-79.4% | $113.8M+5.9% | $221.1M+244% | $138.15M+2,000% | ||
| —— | —— | —— | —— | —— | ||
| —— | $0— | —— | —— | —— | ||
| $28K— | $0— | —— | —— | —— | ||
| $312K-1.0% | $332K-34.8% | $289K-40.4% | $338K-23.9% | $315K-23.7% | ||
| —— | —— | —— | —— | $97.57M— | ||
| -$34.45M-184% | -$134.08M-211% | -$110.55M— | -$26.76M— | $41.01M— | ||
| $53K-99.7% | $75K-99.6% | $2.37M-84.5% | $2.37M-84.6% | $17.52M+5,853% | ||
| $2.76M-66.2% | $3.44M-64.7% | $4.44M-60.4% | $6.39M-41.6% | $8.18M-17.8% | ||
| —— | $1.69M— | $1.27M— | $847K— | $423.5K— | ||
| —— | —— | —— | $5.14M-72.6% | -$1.04M-104% | ||
| -$6.2M— | $1.74M— | $71K— | —— | —— | ||
| -$7.77M-16.3% | -$7.48M-16.5% | -$7.2M-16.7% | -$6.93M-16.8% | -$6.67M-27.1% | ||
| -$18.34M-294% | -$19.35M-263% | -$7.45M— | $3.05M— | $9.46M— | ||
| $38.41M+15.6% | $38.29M+23.2% | $37.43M+31.0% | $35.63M+34.1% | $33.23M+68.9% | ||
| $5.68M+6.9% | $5.88M+14.5% | $5.69M+14.4% | $5.5M+14.4% | $5.31M+26.3% | ||
| -$512K+31.3% | -$571K+25.5% | -$616K+24.7% | -$639K+32.5% | -$745K+9.6% | ||
| $532K-86.1% | $1.7M-45.3% | $2.58M-25.7% | $3.16M+6.2% | $3.83M+0.2% | ||
| $103.13M+92.2% | $0-100% | $17.88M— | $35.76M— | $53.65M— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $3.15M-40.7% | $3.41M-45.7% | $3.76M-49.8% | $4.38M-49.5% | $5.31M-43.9% | ||
| -$66.91M— | -$69.73M— | —— | —— | —— | ||
| -$7.77M-16.3% | -$7.48M-16.5% | -$7.2M-16.7% | -$6.93M-16.8% | -$6.67M-27.1% | ||
| —— | —— | —— | —— | —— | ||
| $53K-99.7% | $75K-99.6% | $2.37M-84.5% | $2.37M-84.6% | $17.52M+5,853% | ||
| -$151.59M+25.9% | -$177.24M+12.2% | -$222.6M— | -$249.43M— | -$204.71M— | ||
| -$151.59M+25.9% | -$177.24M+12.2% | -$222.6M— | -$249.43M— | -$204.71M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Sutro Biopharma generate?
- Sutro Biopharma (STRO) generated -$151.6M in operating cash flow over the trailing twelve months.
- What is Sutro Biopharma's free cash flow?
- After $627.0K of capital expenditures, Sutro Biopharma's free cash flow was -$151.6M over the trailing twelve months, up 25.9% year over year.
- Where does Sutro Biopharma's cash flow data come from?
- Every line is extracted from Sutro Biopharma's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
